Health Care & Life Sciences » Pharmaceuticals | YiChang HEC ChangJiang Pharmaceutical Co. Ltd.

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
399
555
855
1,100
1,847
2,974
Cost of Goods Sold (COGS) incl. D&A
146
151
220
250
323
472
Gross Income
253
404
635
850
1,523
2,501
SG&A Expense
187
214
214
366
652
1,230
EBIT
117
232
437
481
872
1,272
Unusual Expense
-
-
29
-
-
-
Non Operating Income/Expense
5
-
8
38
21
13
Interest Expense
62
53
31
8
5
2
Pretax Income
89
205
388
529
863
1,306
Income Tax
16
35
60
85
140
238
Consolidated Net Income
73
170
328
445
722
1,067
Net Income
73
170
328
445
746
1,116
Net Income After Extraordinaries
73
170
328
445
746
1,116
Net Income Available to Common
73
170
328
445
746
1,116
EPS (Basic)
0.16
0.38
0.97
0.98
1.65
2.47
Basic Shares Outstanding
451
451
336
451
452
452
EPS (Diluted)
0.16
0.38
0.98
0.99
1.65
2.47
Diluted Shares Outstanding
451
451
336
451
452
452
EBITDA
154
272
467
511
922
1,344
Other Operating Expense
50
42
17
2
-
-
Non-Operating Interest Income
28
27
3
9
17
17
Minority Interest Expense
-
-
-
-
24
49

About YiChang HEC ChangJiang Pharmaceutical Co.

View Profile
Address
Dong YangGuang Park
Dongguan Guangdong 443300
China
Employees -
Website http://www.hec-changjiang.com
Updated 07/08/2019
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. engages in the development, manufacturing and selling of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, cardiovascular diseases and others. Its products include Benzbromarone, Telmisartan, Amlodipine besylate, and Cetirizine hydrochloride. The company was founded on May 11, 2015 and is headquartered in Dongguan, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.